COOPERATIVE STUDY OF CANCER CHEMOTHERAPY

癌症化疗的合作研究

• 批准号: 3556087
• 负责人: James A. Neidhart
• 金额: $ 16.43万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 1987-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556087
• 关键词: Hodgkin's disease; adult human (21+); azacitidine; bleomycin; breast neoplasms; central nervous system neoplasms; combination chemotherapy; cooperative study; cyclophosphamide; dosage; doxorubicin; drug adverse effect; drug metabolism; fluorouracil; histiocytic lymphoma; human subject; human therapy evaluation; lomustine; lung neoplasms; lymphocytic leukemia; lymphoma; lymphosarcoma; melphalan; meningioma; metastasis; methotrexate; multiple myeloma; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; prednisone; procarbazine; radiation therapy dosage; testis neoplasms; vincristine

Patients who have cancer will be treated with Phase III protocols of the Southwest Oncology Group in an interdisciplinary approach utilizing surgery, radiotherapy, chemotherapy (which includes variable schedules and combinations of drugs, including both investigational agents and already proven and accepted drugs, either alone or in combination with radiotherapy; these forms of therapy would represent the current most effective drug combinations identified by group studies), and immunotherapy. Patients who are unresponsive to the above therapy will be managed with new experimental agents, which have been carefully evaluated for dosage and toxicity, and which show suggestive evidence of anti-tumor effect in specific malignancies. These will represent the Phase II protocol studies of the Southwest Oncology Group. Ancillary studies utilizing patient material being evaluated in the above protocols will be coordinated with research activities of other departments in the areas of pathology, immunology, biochemistry, pharmacology, and anatomy through independent grant support.

癌症患者将接受 III 期方案的治疗 西南肿瘤学小组采用跨学科方法利用 手术、放疗、化疗（包括可变的时间表和 药物组合，包括研究药物和已经 已被证明和接受的药物，无论是单独使用还是与其他药物组合使用 放射治疗；这些形式的治疗将代表当前最 通过小组研究确定的有效药物组合），以及 免疫疗法。 对上述治疗无反应的患者将被 使用经过仔细评估的新实验剂进行管理 剂量和毒性，并显示出抗肿瘤的暗示证据 对特定的恶性肿瘤有作用。 这些将代表第二阶段 西南肿瘤学组的方案研究。 利用上述评估的患者材料进行辅助研究 方案将与其他部门的研究活动协调 在病理学、免疫学、生物化学、药理学等领域 通过独立拨款支持进行解剖学研究。